Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Nanobiotix S.A. files with the SEC in its annual reports.
In EUR millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
3.48
2.54
2.51
2.65
4.78
36.2
-7.19
32.6
Research and development
20.9
30.4
24.3
30.4
32.6
38.4
40.5
23.1
Selling, general and administrative
12.7
18.9
14.6
19.4
17.9
22
20.5
20.4
Operating income
-30.1
-46.8
-36.4
-52.6
-46.7
-26.8
-68.4
-10.8
Interest expense
1.45
4.97
-2.65
0.78
13.9
14.8
7.49
15.2
Interest income
1.17
0.84
0.2
6.36
3.53
2
7.85
2.09
Pre-tax income
-30.3
-50.9
-33.6
-47
-57
-39.7
-68.1
-24
Income tax
0
0
0.01
0.01
0.01
0.12
0.1
0
Net income
-30.3
-50.9
-33.6
-47.1
-57
-39.7
-68.1
-24
EPS, basic
-1.55
-2.35
-1.38
-1.35
-1.64
-1.08
-1.44
-0.50
EPS, diluted
-1.55
-2.35
-1.38
-1.35
-1.64
-1.08
-1.44
-0.50
Balance sheet
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
36.2
35.1
119
83.9
41.4
75.3
49.7
52.8
Total current assets
46.1
125
93.1
52.4
87.3
61.5
62.8
Property, plant and equipment
8.38
9.39
8.26
8.19
7.12
6.25
5.54
4.57
Intangible assets
0.1
0.16
0.02
0
0
0.01
0.01
0.01
Total assets
56.2
134
102
59.8
93.9
67.4
67.8
Accounts payable
7.77
7.11
6.48
9.62
18.2
20
9.12
Total current liabilities
14.3
19
36.8
37.9
49.9
58.9
57.5
Total liabilities
58.1
63.6
75
86.8
95.7
133
152
Paid-in capital
153
256
256
256
313
313
314
Retained earnings
-227
-317
-380
-401
Total equity
14.2
-1.91
70.5
26.8
-27
-1.84
-65.7
-84.5
Total liabilities and equity
56.2
134
102
59.8
93.9
67.4
67.8
Cash flow statement
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-30.3
-50.9
-33.6
-47
-57
-39.7
-68.1
-24
Cash from operations
-26
-41.2
-27.5
-29.9
-37.1
-12.5
-19.6
-33.4
Capital expenditures
-0.42
-1.09
-0.1
-0.23
-0.09
-0.33
-0.85
-0.54
Cash from investing
0.07
-1.46
-0.11
-0.24
0.14
-0.35
-0.96
-0.58
Debt issued
16
14
10.4
0
0
0
0
42.9
Debt repaid
-0.5
-0.25
-2.83
-3.64
-2.97
-3.08
-3.55
Stock issued
72
Cash from financing
14.9
41.5
112
-5.18
-5.65
46.8
-5.14
37.4
Exchange rate effect
0.05
0.03
-0.06
0.06
0.08
-0.05
0.09
-0.4
Net change in cash
-11
-1.11
84.1
-35.2
-42.5
33.9
-25.5
3.01
Free cash flow
-26.4
-42.3
-27.6
-30.1
-37.2
-12.8
-20.4
-34
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Operating margin
-33.2%
Operating income / revenue.
Pre-tax margin
-73.5%
Pre-tax income / revenue.
Net margin
-73.5%
Net income / revenue.
FCF margin
-104.2%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-102.5%
Cash from operations / revenue.
Return on assets (ROA)
-35.5%
Net income / average total assets.
R&D / revenue
70.9%
Research and development expense / revenue.
SG&A / revenue
62.5%
Selling, general and administrative expense / revenue.
Capex / revenue
1.7%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue CAGR, 3y
89.7%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
67.0%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
0.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
4.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-12.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.09x
Current assets / current liabilities.
Quick ratio
0.92x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.92x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
224.7%
Total liabilities / total assets.
Interest coverage
-0.71x
Operating income / interest expense.
Working capital
€5.2M
Current assets - current liabilities.
Goodwill and intangibles / assets
0.0%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.48x
Revenue / average total assets.
Fixed asset turnover
6.45x
Revenue / average property, plant and equipment.
Per share
Metric
Value
How it is calculated
EPS, diluted
-€0.50
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-€0.50
Net income per basic share, as reported (split-adjusted).
What was Nanobiotix S.A.'s revenue in fiscal 2025?
Nanobiotix S.A. reported revenue of €32.6M for fiscal 2025.
Was Nanobiotix S.A. profitable in fiscal 2025?
No. It reported a net loss of €24.0M.
How much free cash flow did Nanobiotix S.A. generate in fiscal 2025?
Cash from operations of €33.4M minus capital expenditures of €538.0K left free cash flow of -€34.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.